Living Donor Liver Transplantation With Vena Cava Replacement

Basit Öğe Kaydı
dc.authoridYilmaz, Sezai/0000-0002-8044-0297
dc.authoridKaragul, Servet/0000-0003-1964-2516
dc.authoridince, volkan/0000-0002-0714-490X
dc.authoridKirmizi, Serdar/0000-0001-9385-1450
dc.authoridKayaalp, Cuneyt/0000-0003-4657-2998
dc.authorwosidKayaalp, Cuneyt/AAH-1764-2021
dc.authorwosidYilmaz, Sezai/ABI-2323-2020
dc.authorwosidKaragul, Servet/K-3020-2015
dc.authorwosidince, volkan/M-7325-2017
dc.contributor.authorYagci, M. A.
dc.contributor.authorTardu, A.
dc.contributor.authorKaragul, S.
dc.contributor.authorInce, V.
dc.contributor.authorErtugrul, I.
dc.contributor.authorKirmizi, S.
dc.contributor.authorUnal, B.
dc.date.accessioned2024-08-04T20:40:17Z
dc.date.available2024-08-04T20:40:17Z
dc.date.issued2015
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjectives. This study sought to evaluate the indications, techniques, and results of inferior vena cava (IVC) replacement at living donor liver transplantation (LDLT). Materials and Methods. We performed 821 LDLTs and 11 (1.3%) patients required concomitant IVC replacement. We analyzed the indications, replacement materials, and outcomes. Results. Right, left, and left lateral liver lobes were transplanted in 7, 2, and 2 patients, respectively. The indications for IVC replacement were thrombosis/fibrosis in 7 patients (Budd-Chiari 4, hereditary tyrosinemia 1, congenital hepatic fibrosis 1, cryptogenic 1), involvement with mass in 3 patients (Echinococcus alveolaris 2, hepatoblastoma 1) and iatrogenic narrowing at IVC in 1 patient. Cryopreserved grafts (aorta n = 5, IVC n = 4, iliac vein n = 1) or synthetic graft (n = 1) were used for replacements. In 1 patient, hepatic outflow obstruction developed at 39 days and was treated successfully by interventional radiology. There was only 1 hospital mortality (8.9%) that was unrelated to caval replacement (subarachnoid hemorrhage). Of the remaining patients, the caval grafts were patent after a mean 7.7 months of follow-up (range 1 to 17 months). Conclusions. Although rare, IVC replacement can be necessary at LDLT. Budd-Chiari and E. alveolaris are the main underlying diseases for replacement requirements. Caval replacement with cryopreserved vascular grafts can provide successful short-term and long-term patency.en_US
dc.identifier.doi10.1016/j.transproceed.2015.04.019
dc.identifier.endpage1457en_US
dc.identifier.issn0041-1345
dc.identifier.issn1873-2623
dc.identifier.issue5en_US
dc.identifier.pmid26093741en_US
dc.identifier.scopus2-s2.0-84931294201en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1453en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2015.04.019
dc.identifier.urihttps://hdl.handle.net/11616/96825
dc.identifier.volume47en_US
dc.identifier.wosWOS:000357066800053en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBudd-Chiari-Syndromeen_US
dc.subjectHepatocellular-Carcinomaen_US
dc.subjectSingle-Centeren_US
dc.subjectGraften_US
dc.subjectReconstructionen_US
dc.subjectPreservationen_US
dc.subjectExperienceen_US
dc.subjectRecipientsen_US
dc.subjectResectionen_US
dc.titleLiving Donor Liver Transplantation With Vena Cava Replacementen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu